Basilea Pharmaceutica (OTCMKTS:BPMUF) Hits New 52-Week High – Should You Buy?

Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $84.00 and last traded at $84.00, with a volume of 10 shares trading hands. The stock had previously closed at $77.40.

Basilea Pharmaceutica Trading Up 8.5%

The firm has a 50-day simple moving average of $76.76 and a 200-day simple moving average of $69.81. The company has a current ratio of 6.60, a quick ratio of 5.97 and a debt-to-equity ratio of 0.44.

About Basilea Pharmaceutica

(Get Free Report)

Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000 and headquartered in Basel. It focuses on developing and commercializing medicines for serious bacterial and fungal infections. The company’s products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic used for certain serious bacterial infections. Basilea makes its medicines available in multiple countries through a combination of its own commercial activities and partnerships.

Recommended Stories

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.